XTLB
NASDAQXTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. (XTLB) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for XTLB, including 1 SEC filing. The most recent was published Oct 14, 2026.
Financial highlights
Full financials- Revenue, FY2025
- $60.0K
- Revenue growth
- -86.7%
- Net income, FY2025
- -$6.97M
- Net margin
- -11615.0%
- Cash
- $76.0K
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks9-100%
2026-05-172026-11-08
Mix190d
- SEC Filings1(100%)
Activity · 52 weeks3626 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 20-F filed by XTL Biopharmaceuticals Ltd.20-F - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- PRXTL Completed the Acquisition of Psyga Bio Ltd.expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic juncture and with unprecedented regulatory tailwinds in the US, XTL completes its strategic transformation and becomes a dedicated company in the field of global psychedelic medicine; operations will focus on an advanced clinical pipeline, a licensed GMP manufacturing facility, and a unique intellectual property (IP) library. HERZLIYA, ISRAEL, June 30, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ and TASE: XTLB), is pleased to announce today the completion of the strategic
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- PRXTL Announces Receipt of Staff Delist Determination from NasdaqRAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated May 18, 2026, notifying the Company that since the Company has not yet filed its Annual Report on Form 20-F for the year ended December 31, 2025, it no longer complies with Nasdaq's Listing Rule Listing Rule 5250(c)(1) which requires companies to timely file all required periodic financial reports with the SEC. Nasdaq informed the Company that this matter serves as an additional basis for de
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form NT 20-F filed by XTL Biopharmaceuticals Ltd.NT 20-F - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- PRXTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin TechnologiesTransaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven Approved Phase 2a Human Clinical Trials Expected to Begin Patient Enrollment in the Near Future Licensed GMP-Ready Pharmaceutical Facility for Botanical and Synthetic Psilocybin Manufacturing Creates Strategic Commercialization Advantage Milestone-Based Structure Provides Significant Additional Long-Term Value Creation RAMAT GAN, ISRAEL, April 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the "Company" or "XTL") announced today that it has entered into a definitive share purchase agreement (the "Purchase Agreement") to acq
- INSIDERSEC Form 3 filed by new insider Segal Niv3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hillel Fain Osnat3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- PRXTL Biopharmaceuticals Announces ADS Ratio ChangeRAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on March 25, 2026 (the "Effective Date"). For the Company's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-four revers
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- PRXTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request HearingRAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- SECSEC Form 6-K filed by XTL Biopharmaceuticals Ltd.6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)
- PRXTL Update on Recent DevelopmentsRAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company's Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for February 17, 2026 to approve a private placement of up to US$2 million. Management of the Company believes that the completion of the proposed transaction to acquire 85% of the shares of NeuroNOS Ltd.,
XTLB FAQ
9 questionsWhat does XTL Biopharmaceuticals Ltd. do?
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL...What is the latest news on XTLB?
In the last 30 days Quantisnow tracked 1 wire item for XTLB: 1 SEC filing. The most recent was published on October 14, 2026.What is XTLB revenue?
XTL Biopharmaceuticals Ltd. (XTLB) reported $60.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 86.7% from the year before.Is XTLB profitable?
No. XTL Biopharmaceuticals Ltd. reported a net loss of $6.97M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does XTLB have?
XTL Biopharmaceuticals Ltd. reported $76.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does XTLB stock trade?
XTL Biopharmaceuticals Ltd. (XTLB) is listed on NASDAQ.What sector and industry is XTLB in?
XTL Biopharmaceuticals Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to XTLB?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare XTLB side-by-side with any of them on Quantisnow.How can I track XTLB on Quantisnow?
Quantisnow aggregates XTL Biopharmaceuticals Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XTLB to receive live email and push alerts on every new disclosure.